Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies

Expert Opinion on Pharmacotherapy
Dick C Chan, Gerald F Watts

Abstract

Dyslipoproteinaemia is a cardinal feature of the metabolic syndrome that accelerates atherosclerosis. It is usually characterized by high plasma concentrations of triglyceride-rich and apolipoprotein B (apoB)-containing lipoproteins, with depressed concentrations of high-density lipoprotein (HDL). Drug interventions are essential for normalizing metabolic dyslipidaemia. This review discusses the mechanisms and treatment for dyslipidaemia in the metabolic syndrome and type 2 diabetes. A comprehensive understanding of the pathophysiology and pharmacotherapy of dyslipidaemia in the metabolic syndrome and diabetes. Dysregulation of lipoprotein metabolism may be due to a combination of overproduction of triglyceride-rich lipoproteins, decreased catabolism of apoB-containing particles, and increased catabolism of HDL particles. These abnormalities may be consequent on a global metabolic effect of insulin resistance and an excess of both visceral and hepatic fat. Lifestyle modifications may favourably alter lipoprotein transport in the metabolic syndrome. Patients with dyslipidaemia and established cardiovascular disease should receive a statin as first-line therapy. Combination with other lipid-regulating agents, such as ezetimibe, f...Continue Reading

References

Jan 27, 1975·JAMA : the Journal of the American Medical Association
Aug 1, 1992·The American Journal of Clinical Nutrition·A M Dattilo, P M Kris-Etherton
Nov 11, 1992·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·J R PatschW Patsch
Oct 1, 1987·The Journal of Clinical Investigation·R H Eckel, T J Yost
Dec 1, 1986·Journal of the American College of Cardiology·P L CannerW Friedewald
Jan 1, 1986·Metabolism: Clinical and Experimental·P T WilliamsK M Vranizan
Mar 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·J R PatschA M Gotto
Sep 1, 1995·Arteriosclerosis, Thrombosis, and Vascular Biology·L LagrostP Gambert
Feb 1, 1993·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·A GawJ Shepherd
May 1, 1993·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·A D Sniderman, K Cianflone
Oct 1, 1995·Baillière's Clinical Endocrinology and Metabolism·C J Packard
Mar 1, 1997·Metabolism: Clinical and Experimental·B W Patterson
May 1, 1997·The American Journal of Clinical Nutrition·W S Harris
Apr 4, 1998·The American Journal of Cardiology·E A SteinP Laskarzewski
Jun 11, 1998·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·F M RichesG R Thompson
Oct 24, 1998·Endocrinology and Metabolism Clinics of North America·H N Ginsberg
Nov 10, 1998·Circulation·B StaelsJ C Fruchart
Nov 24, 1998·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·H E Bays, C A Dujovne
Apr 20, 1999·The Journal of Clinical Investigation·B LamarcheG F Lewis
Oct 8, 1999·Clinica Chimica Acta; International Journal of Clinical Chemistry·B LamarcheG F Lewis
Apr 6, 2000·Current Opinion in Lipidology·P T PriceS D Clarke
Aug 23, 2000·The Journal of Clinical Investigation·H N Ginsberg
Jan 6, 2001·Journal of Cardiovascular Risk·H N Ginsberg, L S Huang
Jan 9, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·A von EckardsteinG Assmann
May 3, 2001·The New England Journal of Medicine·J TuomilehtoUNKNOWN Finnish Diabetes Prevention Study Group
Sep 29, 2001·The American Journal of Cardiology·H N Ginsberg, D R Illingworth
Jan 5, 2002·The New England Journal of Medicine·B G BrownJ J Albers
Feb 8, 2002·The New England Journal of Medicine·William C KnowlerUNKNOWN Diabetes Prevention Program Research Group
Jul 30, 2002·Metabolism: Clinical and Experimental·Dick C ChanP Hugh R Barrett
Aug 21, 2002·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·F PontB Vergès

❮ Previous
Next ❯

Citations

Jul 26, 2012·Metabolic Syndrome and Related Disorders·Caroline Schmidt, Göran M L Bergström
Apr 16, 2013·Nutrients·Boudewijn KlopManuel Castro Cabezas
Sep 26, 2013·Nature Reviews. Cardiology·Gerald F WattsDick C Chan
Sep 4, 2012·Current Cardiology Reports·Niina Matikainen, Marja-Riitta Taskinen
Mar 7, 2012·The Medical Clinics of North America·Payal Kohli, Christopher P Cannon
Oct 22, 2011·Biochimica Et Biophysica Acta·A C I BoullartA F Stalenhoef
Dec 17, 2015·Nature Reviews. Endocrinology·D John Betteridge, Rafael Carmena
Jul 16, 2011·Expert Opinion on Pharmacotherapy·Altan Onat
Jan 28, 2012·Expert Opinion on Therapeutic Targets·Laia SalvadóManuel Vázquez-Carrera
Jun 23, 2015·Diabetology & Metabolic Syndrome·Fatima Al Hannan, Kevin Gerard Culligan
Mar 17, 2012·Atherosclerosis·Anna CabréJordi Salas-Salvadó
Jan 13, 2015·Atherosclerosis. Supplements·Lorenzo Arnaboldi, Alberto Corsini
Jul 19, 2016·Journal of Clinical Pharmacy and Therapeutics·H-S KimK-H Yoon
Sep 1, 2011·Expert Review of Cardiovascular Therapy·Gerald F Watts, Fredrik Karpe
Apr 19, 2013·Expert Opinion on Investigational Drugs·Ruben Hernandez-AlcocebaJesus Prieto
Jun 9, 2020·Expert Review of Cardiovascular Therapy·N S NurmohamedE S G Stroes
Sep 21, 2011·The Medical Journal of Australia·Helena J TeedeUNKNOWN Guideline Development Groups
May 26, 2017·Journal of Basic and Clinical Physiology and Pharmacology·Štefan TóthDaniel Pella
Dec 18, 2018·Expert Review of Endocrinology & Metabolism·N S KakolyA E Joham
Jun 16, 2011·BioFactors·Gian Paolo LittarruGerald F Watts
Dec 6, 2020·Current Opinion in Endocrinology, Diabetes, and Obesity·Nick S R LanGerald F Watts

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.